In addition, ablation of DYRK1B increases ROS production to over the threshold of affordable ROS levels and enhances cell death in cancer cells when exposed to anticancer drugs [33,34], indicating that knockdown or inactivation of DYRK1B may have a synergistic effect with chemotherapeutic drugs on TNBC cells. This evidence concerns the gene DYRK1B and cancer.